81 filings
Page 2 of 5
6-K
bb6rjqylfhb il7h
5 Oct 23
Current report (foreign)
7:00am
6-K
zwdrdd4y
15 Sep 23
Current report (foreign)
4:05pm
6-K
hj21hdeaigxevkw
15 Sep 23
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
7:00am
6-K
ua3i ojiy1rb
14 Sep 23
OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares
10:05am
6-K
u0amvou
14 Sep 23
OKYO Pharma Limited Announces Withdrawal of Public Offering
10:03am
6-K
evqftg5t2d4m
13 Sep 23
OKYO Pharma Announces Public Offering of Ordinary Shares
4:05pm
6-K
dsfym4
8 Sep 23
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease
7:00am
6-K
7csjd
30 Aug 23
Current report (foreign)
7:00am
6-K
5av9hm4h 1h
29 Aug 23
Current report (foreign)
7:00am
6-K
owwp85dt9
15 Aug 23
Current report (foreign)
9:00am
6-K
5vioh sk3aivw9
31 Jul 23
OKYO Pharma Limited Announces Withdrawal of Public Offering
6:02am
6-K
vxbqpv09k
28 Jul 23
OKYO Pharma Announces Proposed Public Offering of Ordinary Shares
5:25pm
6-K
elc0yy9rc hpygco6
28 Jul 23
OKYO Pharma Limited Receives Nasdaq Deficiency Notice
5:05pm
6-K
x6orl91 q3
28 Jul 23
Current report (foreign)
7:00am
6-K
mhs t8h9pf8u
27 Jul 23
OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer
12:27pm
6-K
52c717bg6db9g j2v
6 Jun 23
OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease
9:30am
6-K
5bqv7wguh
22 May 23
Current report (foreign)
7:00am
6-K
ulgilpnkmf5obl9vtjk
19 May 23
ADS Program collapse - Commencement of trading of new ordinary shares on The Nasdaq Capital Market
7:00am
6-K
lkq6r
15 May 23
Current report (foreign)
7:00am
6-K
84g9pnl7wergf1uwutj
11 May 23
OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform
7:00am